Abstracts tagged "Medicare"

Abstract Number: 1549 • ACR Convergence 2024
Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022
Celestine He¹, Zhonghan Li¹, Sumanth Chennareddy² and Chrisanna Dobrowolski³, ¹Icahn School of Medicine, Mount Sinai, New York, NY, ²Icahn School of Medicine, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Treatment of Systemic Lupus Erythematosus (SLE) has evolved substantially in the past decade. In 2011, the FDA approved belimumab, the first targeted monoclonal antibody…
Abstract Number: 2060 • ACR Convergence 2024
Clustering Analysis of Immune Cell Subtypes and Clinical Phenotypes in Idiopathic Inflammatory Myopathy
xiaoyan xing¹, Yuhui Li² and Jing He³, ¹Department of Rheumatology and Immunology and Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China, Beijing, China, ²Peking University, BeiJing, China, ³Rheumatology, Beijing, China
Background/Purpose: Immune cell profiling plays a pivotal role in the pathogenesis of idiopathic inflammatory myopathy (IIM). Characterizing immune cell subtypes, such as CD4+ T cells,…
Abstract Number: 0141 • ACR Convergence 2023
In-patient Outcome Difference in Systemic Lupus Erythematous Patient Between Medicare and Non-Medicare Group, a Nationwide Analysis
Mishouri Paul, Prodip Paul, Birendra Amgai and Julio Ramos, Geisinger Community Medical Center, Scranton, PA
Background/Purpose: Systemic lupus erythematosus is a chronic inflammatory disorder that significantly burdens our health system. The study aimed to understand the difference in in-patient outcomes…
Abstract Number: 0181 • ACR Convergence 2023
Increased Prevalence of and Acute Hospital Events Among Medicare Systemic Lupus Erythematosus Patients Living in Socially Vulnerable Counties in the United States
Emily Cosentino, John Pearce and Jim Oates, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is more prevalent and has greater adverse health outcomes in women, minorities, and individuals with low socioeconomic status (SES), particularly…
Abstract Number: 0457 • ACR Convergence 2023
Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival
Deanna Jannat-Khah¹, Jeffrey R Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne Bass⁵, ¹Hospital For Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

Background/Purpose: There is a dearth of knowledge around the safety of biologic disease modifying antirheumatic drugs (bDMARDS) in immune checkpoint inhibitor (ICI)-treated rheumatoid arthritis (RA)…
Abstract Number: 0967 • ACR Convergence 2023
Overall Survival in Patients with versus Without Rheumatoid Arthritis Initiating Immune Checkpoint Inhibitors for Metastatic Non Small Cell Lung Cancer
Deanna Jannat-Khah¹, Jeffrey R Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne Bass⁵, ¹Hospital For Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) increase one-year survival in metastatic non-small cell lung cancer (mNSCLC) from 49% to 69% with chemotherapy-based regimens. Patients with rheumatoid…
Abstract Number: 1615 • ACR Convergence 2023
Therapeutic Hydroxychloroquine Blood Levels Are Cost Effective and May Reduce Health Disparities by Reducing Lupus Hospitalizations
Shivani Garg¹, Giancarlo Valiente², Lexie Kolton³, Callie Saric³, Betty Chewning⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴University of Wisconsin, School of Pharmacy, Madison, WI
Background/Purpose: Studies show factors including daily hydroxychloroquine (HCQ) dosing or nonadherence affect blood concentrations risking 6-fold higher lupus (or SLE) flares requiring hospitalization. Given disparities…
Abstract Number: 1619 • ACR Convergence 2023
Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis
Carolyn Thorpe, Ryan Hickson, Sherrie Aspinall, Vimal Derebail, Xinhua Zhao, Joshua Thorpe, Binxin Cao, Alexa Ehlert, Ronald Falk and Susan Hogan, University of North Carolina, Chapel Hill, NC
Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…
Abstract Number: 1799 • ACR Convergence 2023
Association of Pregabalin vs Gabapentin with Incident Congestive Heart Failure in Patients with Non-Cancer Pain
Elizabeth Park¹, Laura Daniel², Alyson Dickson³, Meghan Corriere⁴, Puran Nepal⁵, Kathi Hall⁴, Dale Plummer⁴, William Dupont⁴, Katherine Murray⁴, C. Michael Stein³, Wayne Ray⁴ and Cecilia Chung⁶, ¹Columbia University Irving Medical Center, New York, NY, ²University of Miami, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Vanderbilt University, Nashville, TN, ⁵University of Miami Health System and Miller School of Medicine, Miami, FL, ⁶University of Miami, Miami, FL
Background/Purpose: Chronic pain affects 30% of all patients in developed countries, accounting for up to 35% of prescriptions in acute care settings. Non-opioid pain medications…
Abstract Number: 1850 • ACR Convergence 2023
Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Andriko Palmowski¹, Eric Roberts², Jing Li², Emma Kersey², Rachael Stovall², Frank Buttgereit³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of California San Francisco, San Francisco, CA, ³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ⁴University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…
Abstract Number: 2528 • ACR Convergence 2023
Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
Min Kim¹, Vanessa C. Brunetti¹, Felicia Cosman², Jeffrey Curtis³, E Michael Lewiecki⁴, Matthew Phelan⁵, Peter Samai⁵, Michele McDermott¹, Tzu-Chieh Lin¹, M Alan Brookhart⁶ and Kathleen Hurwitz⁵, ¹Amgen, Inc., Thousand Oaks, CA, ²Columbia University, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵Target RWE, Durham, NC, ⁶Department of Population Health Sciences, Duke University, Durham, NC
Background/Purpose: Recent studies suggest that post-fracture pharmacologic management has been declining in the U.S. despite an increase in the burden of osteoporosis (OP). In light…
Abstract Number: 0707 • ACR Convergence 2022
Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis
Rachel W. Galvao¹, Jeffrey Curtis², Leslie Harrold³, Qufei Wu⁴, Fenglong Xie⁵ and Michael George⁴, ¹Yale University, New Haven, CT, ²University of Alabama at Birmingham, Hoover, AL, ³CorEvitas, LLC, Waltham, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Glucocorticoids (GCs) are used commonly to treat patients with rheumatoid arthritis (RA) and other inflammatory conditions. As clinical trials are often underpowered to assess…
Abstract Number: 1195 • ACR Convergence 2022
Duloxetine and the Risk for Acute Myocardial Infarction and Stroke in Medicare Recipients with Non-Cancer Pain
Meghan Corriere, Alyson Dickson, Laura Daniel, Puran Nepal, Kathi Hall, Dale Plummer, William Dupont, Katherine Murray, Michael Stein, Wayne Ray and Cecilia Chung, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor antidepressant also prescribed for musculoskeletal and other forms of chronic pain. Its dual pharmacologic properties have the potential…
Abstract Number: 2200 • ACR Convergence 2022
Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare
Rahaf Baker¹, Jing Li², Rachael Stovall³, Jeffrey Curtis⁴, Fenglong Xie⁵, Jinoos Yazdany⁶ and Gabriela Schmajuk⁷, ¹Alameda Highland Internal Medicine Residency, Oakland, CA, ²University of California, San Francisco, San Francisco, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of Alabama at Birmingham, Hoover, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶UCSF, San Francisco, CA, ⁷UCSF / SFVA, San Francisco, CA
Background/Purpose: Health services studies increasingly rely on Electronic Health Record (EHR) data to capture medication use. However, the reliability of medication information derived from EHR…
Abstract Number: 0071 • ACR Convergence 2022
Workforce Changes and Characteristics of Adult Rheumatologists in a United States Medicare Claims Analysis
Melissa Mannion¹, Fenglong Xie¹, John FitzGerald², Amy Mudano³, Zihan Wan¹ and Jeffrey Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of California Los Angeles, Los Angeles, CA, ³Illumination Health, Hoover, AL, ⁴University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Prior studies have projected inadequate growth in the rheumatology provider workforce to keep up with population demand. The objective of this project was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].